Development of inhaled AJ-099 for the treatmentt of M. abscessus pulmonary disease
| Reference number | |
| Coordinator | Linköpings universitet - Inst f biomedicinska & kliniska vetenskaper |
| Funding from Vinnova | SEK 2 000 000 |
| Project duration | April 2025 - February 2028 |
| Status | Ongoing |
| Venture | Eurostars |
Purpose and goal
At Linköping University, we aim to assess the immune-modulatory potential of AJ-099 in M. abscessus-infected primary human macrophages. Using cells from diverse donors provides a clinically relevant model. We will explore how AJ-099 influences macrophage activation and cytokine/chemokine responses to enhance bacterial clearance. This approach may limit resistance and support its use as a host-directed therapy.
Expected effects and result
We expect AJ-099 to enhance macrophage immune responses, leading to reduced intracellular M. abscessus growth. Live-cell imaging will reveal dynamic changes in host-pathogen interactions. If AJ-099 boosts bacterial clearance while modulating immune signaling, it supports its potential as a host-directed therapy with reduced risk of resistance development.
Planned approach and implementation
An in vitro assay using M. abscessus-infected macrophages will be developed to test AJ-099’s dose-dependent effects. Conditions will be optimised, and their impact on bacterial load evaluated. Synergistic effects with other agents will be assessed. The compound’s influence on cytokine expression and macrophage polarization will be analysed to explore its potential as a host-directed therapy.